9.60 +0.26 (2.78%)
Pre-Market: 8:16AM EST
|Bid||0.00 x 1800|
|Ask||11.00 x 2900|
|Day's Range||9.14 - 9.41|
|52 Week Range||4.15 - 10.88|
|Beta (5Y Monthly)||1.55|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Zacks.com featured highlights include: CNX Midstream Partners LP, Akoustis Technologies, CRH Medical, Mesoblast and Photronics
Picking breakout stocks is one of the most-favored methods for those utilizing an active investing approach since this strategy offers the promise of superlative returns.
Mesoblast Limited (Nasdaq: MESO) announced that the United States Food and Drug Administration (US FDA) has confirmed receipt of Mesoblast's filing of clinical efficacy and safety data for remestemcel-L in its rolling Biologics License Application (BLA) for the treatment of children with steroid-refractory acute graft versus host disease (SR-aGVHD). The final module will be filed during January, and Mesoblast will request an expedited FDA review of the BLA under the product candidate's existing Fast Track designation.
Even if it's not a huge purchase, we think it was good to see that William A. Burns, the Independent Non-Executive...
As you might know, Mesoblast Limited (ASX:MSB) recently reported its first-quarter numbers. Revenues of US$17m crushed...
If you're interested in Mesoblast Limited (ASX:MSB), then you might want to consider its beta (a measure of share...
Statistically speaking, long term investing is a profitable endeavour. But unfortunately, some companies simply don't...
Mesoblast Limited (NASDAQ: MESO ) product rexlemestrocel-L has received Orphan Drug Destination from the U.S. Food and Drug Administration for prevention of gastrointestinal bleeding in patients with left ...
Mesoblast (MESO) begins the rolling submission of a BLA for its lead product, candidate remestemcel-L, to the FDA for treating children with steroid-refractory acute graft versus host disease.
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! Silviu Itescu became the CEO of Mesoblast Limited (ASX:MSB) in 2011. First, this article will compare CEO compensa...